Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.520 -0.250 (-4.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
2 Risky Stocks With Massive Potential
Neither is doing well this year. 
Via The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy Now?
The company has grabbed plenty of headlines recently. 
Via The Motley Fool
2 Cathie Wood Stocks I'm Bullish On
These two next-gen biotechs could be outstanding buys for patient investors. 
Via The Motley Fool
The 7 Best Cathie Wood Stocks to Buy Now: November Edition
Dive into the dynamic world of Cathie Wood stocks, wagering on the disruptive tech gems shaping tomorrow's investment landscape. 
Via InvestorPlace
2 Reasons to Buy Recursion Pharmaceuticals, and 1 Reason to Sell
Pioneering businesses tend to carry big risks, but also the potential for big rewards. 
Via The Motley Fool
3 Extra-Speculative Stocks That Could Make You Very, Very Rich
Speculative stocks are a growth investor's dream—potential for untold riches, if you can find the stocks that will survive. 
Via InvestorPlace
1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid
One of these players could win in AI -- and in the healthcare market, in general. 
Via The Motley Fool
Topics Artificial Intelligence
2 AI Stocks That Aren't Worth the Hype
Even if you're bullish on AI, you may want to think twice about buying shares of these two companies. 
Via The Motley Fool
Topics Artificial Intelligence
Is Recursion Pharmaceuticals Stock a Buy?
This small-cap stock hopes to revolutionize drug discovery with the help of AI. 
Via The Motley Fool
Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?
On Monday, Cathie Wood-led Ark Invest made a notable move by selling nearly $4 million worth of NVIDIA Corp (NASDAQ:NVDA) shares. This ... 
Via Benzinga
Topics Artificial Intelligence
2 Cathie Wood Stocks That Could Deliver Exponential Returns
These two cutting-edge healthcare companies could be significantly undervalued right now. 
Via The Motley Fool
AI Investing: 12 Possible Ways To Maximize Your Returns
It all comes down to playing it smart and doing your research and to help you with that we present 12 micro/small cap AI&R stocks with descriptions of their businesses and their price-to-sales ratios,... 
Via Talk Markets
Topics Artificial Intelligence
Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend
Ginkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend of tomorrow using the big data of today. 
Via InvestorPlace
3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
Cathie Wood is loading up on these healthcare stocks. 
Via The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
They're both liable to grow by a lot, but one of them is a safer bet in the near term. 
Via The Motley Fool
3 AI Drug Discovery Stocks to Watch
The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies. 
Via The Motley Fool
Topics Artificial Intelligence
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Find out why analysts have such high expectations for these stocks. 
Via The Motley Fool
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Where Will Recursion Pharmaceuticals Be in 3 Years?
This biotech could still be a long way from having a drug on the market in 2026. 
Via The Motley Fool
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months. 
Via The Motley Fool
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
These biotech stocks to buy and hold offer tremendous upside blending long-term potential with healthcare advances. 
Via InvestorPlace
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
The famous growth investor has been making some interesting stock moves lately. 
Via The Motley Fool
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
Both businesses have a lot to prove. 
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
 
Via Benzinga
Topics Artificial Intelligence
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.